Charles River Laboratories
CRL
$229.29
+4.84%
Charles River Laboratories is a leading provider of drug discovery and development services, offering animal models for preclinical studies, early development services, and biologics testing. As a dominant player in the contract research organization (CRO) space, it differentiates itself through its integrated portfolio spanning research models, safety assessment, and manufacturing support. The current investor narrative centers on the company's recovery from recent earnings volatility, with attention on margin improvement and the potential for growth acceleration in its Discovery and Safety Assessment segment. Recent analyst upgrades and a strong stock rebound from 2025 lows highlight shifting sentiment around the company's turnaround prospects.…
CRL
Charles River Laboratories
$229.29
Investment Opinion: Should I buy CRL Today?
Rating: Buy. Thesis: CRL is a low-valuation turnaround play with strong free cash flow and improving momentum, supported by analyst upgrades and a consensus Buy rating with an average target of $230.93.
Supporting Evidence: The trailing P/S ratio of 2.51x is near historical lows, offering a margin of safety. Revenue is stable at ~$1 billion per quarter, and free cash flow of $391.3 million provides a 3.9% yield. The forward P/E of 18.2x (based on estimated EPS of $15.29) is reasonable if earnings recover. The stock's 43.2% one-year return and relative strength of 24.8% vs. the S&P 500 confirm strong momentum.
Risks & Conditions: The biggest risks are margin compression (gross margin down to 28.1%) and negative net income. If gross margins fall below 25% or revenue growth turns negative, the thesis would be invalidated, warranting a downgrade to Hold. Conversely, if net income turns positive and margins stabilize, the stock could re-rate higher. Overall, CRL appears undervalued relative to its historical P/S and forward earnings potential, but the turnaround is not yet confirmed.
Sign up to view all
CRL 12-Month Price Forecast
The AI assessment leans bullish due to the attractive valuation and strong free cash flow, but confidence is medium given the negative net income and margin pressures. The base case of gradual improvement is most likely, with a 50% probability. The stock's low P/S provides a margin of safety, but the turnaround must materialize in earnings. An upgrade to high confidence would require two consecutive quarters of positive net income and gross margin expansion above 30%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Charles River Laboratories's 12-month outlook, with a consensus price target around $230.93 and implied upside of +0.7% versus the current price.
Average Target
$230.93
0 analysts
Implied Upside
+0.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$135 - $265
Analyst target range
The stock is covered by 15 analysts, with a consensus recommendation of 'Buy' (mean score of 1.71 on a 1-5 scale, where 1 is Strong Buy). The average target price is $230.93, implying approximately 2.9% upside from the current price of $224.35. The distribution shows 10 analysts rate it Buy or Overweight, 4 at Hold/Neutral, and 1 at Sell, reflecting a generally bullish but cautious sentiment. The target range spans from a low of $135.00 to a high of $265.00, indicating significant uncertainty. The high target of $265 assumes a successful turnaround with margin recovery and growth acceleration, while the low target of $135 implies continued earnings pressure or a recessionary impact. Recent ratings actions show upgrades from Morgan Stanley (Overweight) and CLSA (Outperform), while Mizuho and JP Morgan maintain Neutral. The wide spread between low and high targets (130 points) suggests low conviction among analysts, typical for a stock with volatile earnings. Investors should weigh the bullish consensus against the narrow upside to the average target.
Bulls vs Bears: CRL Investment Factors
CRL presents a classic turnaround story with strong momentum but fundamental challenges. The bull case rests on a low valuation (P/S near historical lows), positive free cash flow, and analyst upgrades signaling a recovery. The bear case highlights negative net income, margin compression, and sluggish revenue growth. The single most important tension is whether the company can restore profitability and margins to historical levels; if it does, the stock could re-rate significantly higher, but if earnings remain under pressure, the current valuation may prove justified. Currently, the evidence slightly favors the bull case given the strong price momentum and low valuation, but the margin and earnings trends require close monitoring.
Bullish
- Strong Recovery Uptrend: CRL has surged 43.2% over the past year, significantly outperforming the S&P 500's 18.4% gain. The stock is trading at $224.35, near the top of its 52-week range ($144.26-$237.86), indicating strong bullish momentum and relative strength.
- Analyst Consensus Buy with Upside: The stock has a consensus 'Buy' rating (mean score 1.71 on a 1-5 scale) from 15 analysts, with an average target price of $230.93, implying 2.9% upside. The high target of $265 suggests potential 18.1% upside if the turnaround succeeds.
- Low Valuation vs. History: The trailing P/S ratio of 2.51x is near the bottom of its 5-year range (which peaked above 25x in 2021). This low multiple reflects market skepticism, but if profitability improves, multiple expansion could drive significant upside.
- Positive Free Cash Flow Generation: Despite recent net losses, CRL generated $391.3 million in free cash flow over the trailing twelve months, providing a free cash flow yield of approximately 3.9%. This cash generation supports debt service and potential investments.
Bearish
- Negative Net Income and Margin Pressure: CRL reported a net loss of $14.8 million in Q1 2026 and a trailing net margin of -3.6%. Gross margin compressed from 34.6% in Q2 2025 to 28.1% in Q1 2026, indicating significant cost pressures that could persist.
- Low Revenue Growth Trajectory: Revenue growth has been minimal, with Q1 2026 revenue of $995.8 million up only 1.2% year-over-year. The multi-quarter trend shows deceleration from mid-single-digit growth in 2024, suggesting a mature CRO market.
- High Debt and Leverage: The debt-to-equity ratio of 0.97 indicates moderate leverage, and interest expense of $26.7 million in Q1 2026 consumes a significant portion of operating income ($119.9 million). Any further earnings deterioration could strain debt servicing.
- Wide Analyst Target Range: Analyst targets range from a low of $135 to a high of $265, a spread of $130 (58% of current price). This wide dispersion indicates low conviction and high uncertainty about the company's earnings recovery trajectory.
CRL Technical Analysis
CRL is in a strong recovery uptrend, with the stock up 43.2% over the past year and currently trading at $224.35, which is 88.5% of its 52-week range ($144.26 to $237.86). This positioning near the upper end of the range suggests bullish momentum, though the stock is not yet at overbought extremes relative to its 52-week high. The 1-year price change of +43.2% significantly outperforms the S&P 500's +18.4%, indicating strong relative strength. Short-term momentum is accelerating sharply, with 1-month and 3-month price changes of +23.0% and +22.0%, respectively, both far outpacing the S&P 500's +0.3% and +4.7%. This divergence from the broader market signals a stock-specific catalyst-driven rally, likely tied to improving fundamentals or analyst upgrades. The 6-month change of +2.1% is modest, but the recent surge suggests a breakout from prior consolidation. Key support lies at the 52-week low of $144.26, while resistance is at the 52-week high of $237.86. A breakout above $237.86 would signal a new uptrend leg, targeting further upside. The stock's beta of 1.40 indicates 40% more volatility than the market, meaning larger swings in both directions. The current price is well above support, but a pullback to the $200 area would not be unusual given the rapid recent gains.
Beta
1.40
1.40x market volatility
Max Drawdown
-33.9%
Largest decline past year
52-Week Range
$144-$239
Price range past year
Annual Return
+36.5%
Cumulative gain past year
| Period | CRL Return | S&P 500 |
|---|---|---|
| 1m | +22.9% | +0.6% |
| 3m | +35.0% | +3.4% |
| 6m | +4.4% | +7.1% |
| 1y | +36.5% | +16.4% |
| ytd | +13.3% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRL Fundamental Analysis
Revenue has been relatively stable, with the most recent quarter (Q1 2026) reporting $995.8 million, up 1.2% year-over-year. However, the multi-quarter trend shows deceleration from 2024's mid-single-digit growth, with Q2 2025 revenue of $1,032.1 million and Q3 2025 of $1,004.9 million. The Discovery and Safety Assessment segment, the largest at $596.9 million, is the primary growth driver, while Research Models and Services ($208.4 million) and Manufacturing Support ($190.5 million) provide diversification. The flat revenue trajectory suggests a mature CRO market, but the company's integrated model supports resilience. Profitability has been volatile, with net income swinging from a loss of $276.6 million in Q4 2025 to a loss of $14.8 million in Q1 2026, reflecting impairment charges. Gross margin has compressed from 34.6% in Q2 2025 to 28.1% in Q1 2026, indicating cost pressures. The trailing twelve-month net margin is negative at -3.6%, but operating margin remains positive at 12.6%, suggesting core operations are profitable before special items. The balance sheet shows a debt-to-equity ratio of 0.97, moderate leverage, and a current ratio of 1.29, indicating adequate liquidity. Free cash flow over the trailing twelve months is $391.3 million, providing a free cash flow yield of approximately 3.9% based on the current market cap. ROE is negative at -4.6% due to recent losses, but the company generates sufficient operating cash flow to cover capital expenditures, with a capital expenditure coverage ratio of 0.73 in Q1 2026.
Quarterly Revenue
$995830000.0B
2026-03
Revenue YoY Growth
+1.2%
YoY Comparison
Gross Margin
28.1%
Latest Quarter
Free Cash Flow
$391290000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRL Overvalued?
Given that net income is negative on a trailing basis (EPS of -$0.01), the P/E ratio is not meaningful. Therefore, we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio is 2.51x, while the forward P/S (based on estimated revenue of $4.25 billion) is approximately 2.37x. The slight discount in the forward multiple implies the market expects revenue growth. Compared to the industry average P/S (data not provided), CRL's P/S of 2.51x is typical for a CRO with stable revenue. However, without explicit industry data, we note that larger CROs like IQVIA trade at higher multiples, suggesting CRL may be at a discount due to its earnings volatility. Historically, CRL's P/S ratio has ranged from 7.8x in early 2026 to over 25x in 2021. The current 2.5x is near the bottom of its 5-year range, indicating the stock is cheap relative to its own history. This low multiple reflects the market's skepticism about earnings recovery, but if profitability improves, multiple expansion could drive significant upside.
PE
-70.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 15x~52x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CRL's primary financial risk is its negative net income trajectory, with a trailing net margin of -3.6% and a net loss of $14.8 million in Q1 2026. Gross margin compression from 34.6% in Q2 2025 to 28.1% in Q1 2026 signals cost pressures that could persist. The debt-to-equity ratio of 0.97 is manageable but interest expense of $26.7 million consumes 22% of operating income, leaving little room for error. Revenue growth is stagnant at 1.2% YoY, indicating limited top-line momentum to offset margin pressures.
Market & Competitive Risks: The stock's beta of 1.40 implies 40% higher volatility than the market, making it sensitive to macro downturns. The CRO industry faces pricing pressure and consolidation, and CRL's reliance on the Discovery and Safety Assessment segment (60% of revenue) creates concentration risk. The wide analyst target range ($135-$265) reflects uncertainty about the company's competitive position and earnings recovery. No recent news highlights emerging threats, but the low valuation suggests the market already discounts significant risks.
Worst-Case Scenario: If revenue growth stalls, margins continue to compress, and the company reports further losses, the stock could fall to its 52-week low of $144.26, representing a 35.7% decline from the current price of $224.35. This scenario could be triggered by a recession reducing pharma R&D spending, a major client loss, or a failed acquisition. The historical max drawdown of -33.88% (from the 52-week high) provides a reference for potential downside.
FAQ
The key risks are: 1) Financial: negative net income and margin compression (gross margin fell to 28.1% in Q1 2026 from 34.6% a year earlier). 2) Competitive: the CRO industry faces pricing pressure and consolidation, and CRL's revenue growth is stagnant at 1.2% YoY. 3) Macro: a beta of 1.40 means the stock is 40% more volatile than the market, so a recession could hit pharma R&D spending. 4) Company-specific: the wide analyst target range ($135-$265) indicates high uncertainty. The most severe risk is a continued earnings decline, which could push the stock to the 52-week low of $144.26, a 35.7% loss.
The 12-month forecast is cautiously optimistic. The base case (50% probability) sees the stock trading in the $215-$240 range, aligning with the analyst average target of $230.93, assuming gradual margin recovery and stable revenue. The bull case (25% probability) targets $240-$265 if profitability returns and the stock re-rates. The bear case (25% probability) sees a decline to $135-$180 if earnings deteriorate further. The most likely scenario is the base case, driven by stable revenue and modest margin improvement. Key assumptions include no major impairments and continued free cash flow generation.
CRL appears undervalued relative to its own history. The trailing P/S ratio of 2.51x is near the bottom of its 5-year range, which peaked above 25x in 2021. Compared to larger CRO peers like IQVIA (which trade at higher multiples), CRL's discount reflects its earnings volatility. The forward P/E of 18.2x (based on estimated EPS of $15.29) is reasonable if earnings recover. The market is pricing in skepticism about the turnaround, but if margins improve, the stock could re-rate significantly. Overall, the valuation implies the market expects continued earnings pressure, but the low multiple provides a margin of safety.
CRL is a good buy for investors with a medium-term horizon who can tolerate volatility. The stock offers a compelling risk/reward: it trades at a P/S of 2.51x, near historical lows, with a consensus analyst target of $230.93 implying 2.9% upside. However, the company is currently unprofitable with a trailing net margin of -3.6%, so the investment thesis hinges on a successful turnaround. The strong free cash flow of $391M provides a cushion. For aggressive investors, the low valuation and positive momentum make it attractive, but conservative investors may prefer to wait for confirmed profitability.
CRL is best suited for a medium- to long-term investment horizon of 12-24 months. The stock's beta of 1.40 and recent 23% one-month gain indicate high short-term volatility, making it risky for short-term traders. The company pays no dividend, so total return depends on price appreciation. The turnaround thesis requires time to play out, as margin recovery and earnings improvement are not imminent. Long-term investors should monitor quarterly earnings for signs of sustained profitability. A minimum holding period of 12 months is recommended to allow the recovery story to develop.